Daniel Ek, the co-founder of Spotify, is pushing his preventive health startup Neko Health into the United States following a $700 million fundraise backed by a mix of celebrity investors, entrepreneurs, and institutional firms. The company plans to open its first US clinic in New York later this year, with rapid national expansion to follow.
What Neko Health Actually Does
Neko operates private, appointment-based clinics that combine full-body scanning technology with blood tests, all processed using custom-built medical equipment and AI analysis. The scans are designed to proactively detect early warning signs of conditions including:
- Skin cancer
- Heart disease
- Diabetes
- Other chronic or latent conditions
The company's core pitch is straightforward: find problems before patients have symptoms, intervene earlier, and extend healthy lifespans. It's a model squarely in the preventive medicine space — sometimes called "longevity medicine" — that has attracted significant capital and cultural attention in recent years.
Co-Founded With a Hardware Background
Ek co-founded Neko with Hjalmar Nilsonne, and the startup is notable for building its own diagnostic hardware rather than relying on existing clinical equipment. That vertical integration is central to the product experience — the clinics are designed to feel premium and efficient, not like a traditional hospital visit.
Neko launched in Sweden and has been refining its model in Europe before making the US push. The $700 million raise signals serious ambition: US healthcare is both the world's largest market and one of its most fragmented, making a well-capitalized rollout essential.
Why This Matters for the Health Tech Market
Neko's expansion arrives as the preventive and longevity health sector is drawing unprecedented investment. Competitors and adjacent players — including Function Health, Fountain Life, and Prenuvo — are all chasing a similar thesis: that wealthy, health-conscious consumers will pay out-of-pocket for diagnostics their insurance won't cover, if the experience and insights are compelling enough.
The AI layer is critical here. Raw scan data is only valuable if it can be interpreted quickly, consistently, and at scale. By embedding AI into its analysis pipeline, Neko aims to reduce the bottleneck that has historically made comprehensive health screening slow and expensive.
What This Means for Founders and Operators
For startup founders and marketers watching this space, a few dynamics are worth noting:
- Consumer health is moving upstream. Products and services that help people avoid illness — rather than treat it — are gaining traction with both investors and paying customers.
- The premium experience model is proving durable. Neko, like competitors, is betting that patients will pay a significant out-of-pocket premium for speed, design, and data ownership — bypassing the traditional insurance-reimbursement model entirely.
- AI-enabled diagnostics need trust as much as accuracy. The harder challenge for Neko in the US won't be the technology — it'll be building the brand credibility required to get people to act on AI-generated health insights.
With $700 million in the bank and a high-profile founder, Neko is well-positioned to make noise in New York. Whether it can scale that model cost-effectively across the US — a market with very different regulatory and competitive dynamics than Sweden — is the real test ahead.
